29 September 2023 - Medison Pharma is pleased to announce the public formulary listing of Qinlock in Canadian provinces: Ontario and Quebec. 

These provinces join Alberta, Saskatchewan, Manitoba, and the Non-Insured Health Benefits (NIHB) program, further broadening the public formulary coverage for adult patients with advanced gastrointestinal stromal tumour who have previously been treated with imatinib mesylate, sunitinib maleate and regorafenib monohydrate.

Read Medison Pharma press release